|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial显示文摘AIM: To investigate efficacy and safety of cetuximab combined with two chemotherapy regimens in patients with unresectable metastatic colorectal cancer (mCRC). METHODS: Randomized patients received cetuximab with 5-fluorouracil (5-FU), folinic acid (FA) and oxaliplatin (FOLFOX) 6 (arm A, n = 74) or 5-FU, FA and irinotecan (FOLFIRI) (arm B, n = 77). KRAS mutation status was determined retrospectively in a subset of tumors (n = 117). RESULTS: No significant difference was found between treatment arms A and B in the progression-free survival (PFS) rate at 9 mo, 45% vs 34%; median PFS, 8.6 mo vs 8.3 mo [hazard ratio (HR) = 1.06]; overall response rate (ORR) 43% vs 45% [odds ratio (OR) = 0.93] and median overall survival (OS), 17.4 mo vs 18.9 mo (HR = 0.98). Patients with KRAS wild-type tumors demonstrated improved PFS (HR = 0.55, P = 0.0051), OS, (HR = 0.62, P = 0.0296) and ORR (53% vs 36%) and in arm A, improved PFS (HR = 0.49, P = 0.0196), OS (HR = 0.48, P = 0.0201) and ORR (56%vs 30%), compared with patients with KRAS mutated tumors. In arm B no significant differences were found in efficacy by KRAS mutation status. Treatment in arms A and B was generally well tolerated. CONCLUSION: This study confirms that combinations of cetuximab with FOLFOX6 or FOLFIRI are effective and significantly improve clinical outcome in KRAS wild-type compared with KRAS mutated mCRC. | Janja Ocvirk Thomas Brodowicz Fritz Wrba Tudor E Ciuleanu Galina Kurteva Semir Beslija Ivan Koza Zsuzsanna Pápai Diethelm Messinger Ugur Yilmaz Zsolt Faluhelyi Suayib Yalcin Demetris Papamichael Miklós Wenczl Zrinka Mrsic-Krmpotic Einat Shacham-Shmueli Damir Vrbanec Regina Esser Werner Scheithauer Christoph C Zie-linski | 2010 | World Journal of Gastroenterology2010，16，25： | 17 |
| 2 | HPV infection and p16 expression in carcinomas of the minor salivary glands 显示文摘 | Markus Brunner Oskar Koperek Fritz Wrba | 2012 | Eur Arch Otorhinolaryngo12012，269，10： | 1 |
| 3 | Hepatocyte GP73 expression in Wilson disease显示文摘 | Lorinda M. Wright Dominik Huster Svetlana Lutsenko Fritz Wrba Peter Ferenci Claus J. Fimmel | 2009 | Journal of Hepatology2009，，3： | 1 |
| 4 | Association of the IL28B genotype with insulin resistance in patients with chronic hepatitis C显示文摘 | Albert Friedrich St?ttermayer Karoline Rutter Sandra Beinhardt Thomas-Matthias Scherzer Andreas Stadlmayr Harald Hofer Fritz Wrba Petra Steindl-Munda Michael Krebs Christian Datz Michael Trauner Peter Ferenci | 2012 | Journal of Hepatology2012，，3： | 1 |
| 5 | Surgery for Gastrointestinal Stromal Tumors of the Stomach显示文摘 | Gerd R. Silberhumer Martin Hufschmid Fritz Wrba Georg Gyoeri Sebastian Schoppmann Barbara Tribl Etienne Wenzl Gerhard Prager Friedrich Laengle Johannes Zacherl | 2009 | Journal of Gastrointestinal Surgery2009，，7： | 1 |
| 6 | The mRNA of L-Type Calcium Channel Elevated in Colon Cancer显示文摘 | Xi-Tao Wang Yasushi Nagaba Heide S. Cross Fritz Wrba Lin Zhang Sandra E. Guggino | 2000 | The American Journal of Pathology2000，，5： | 1 |
| 7 | Mammalian Target of Rapamycin Pathway Activity in Hepatocellular Carcinomas of Patients Undergoing Liver Transplantation显示文摘 | Wolfgang Sieghart Thorsten Fuereder Katharina Schmid Daniel Cejka Johannes Werzowa Fritz Wrba Xiaowei Wang Diego Gruber Susanne Rasoul-Rockenschaub Markus Peck-Radosavljevic Volker Wacheck | 2007 | Transplantation2007，，4： | 1 |
| 8 | TGF-β1 codon 25 gene polymorphism is associated with cirrhosis in patients with hereditary hemochromatosis显示文摘 | Christoph H. ?sterreicher Christian Datz Felix Stickel Claus Hellerbrand Melitta Penz Harald Hofer Fritz Wrba Edward Penner Detlef Schuppan Peter Ferenci | 2005 | Cytokine2005，，2： | 1 |
| 9 | Current value of intraoperative sonography during surgery for hepatic neoplasms显示文摘 | Johannes Zacherl M.D. Christian Scheuba M.D. Martin Imhof M.D. Maximilian Zacherl M.D. Friedrich L?ngle M.D. Peter Pokieser M.D. Fritz Wrba M.D. Etienne Wenzl M.D. Ferdinand Mühlbacher M.D. Raimund Jakesz M.D. Rudolf Steininger M.D | 2002 | World Journal of Surgery2002，，5： | 1 |
| 10 | Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study显示文摘 | Birgit Gruenberger Johannes Schueller Ute Heubrandtner Fritz Wrba Dietmar Tamandl Klaus Kaczirek Rudolf Roka Sandra Freimann-Pircher Thomas Gruenberger | 2010 | Lancet Oncology2010，，12： | 1 |
| 11 | Thioguanin-induced nodular regenerative hyperplasia of the liver-ROC analysis of different MR techniques显示文摘 | Christoph J. Zech Julia Seiderer Walter Reinisch Thomas Ochsenkuhn Wolfgang Schima Joachim Diebold Fritz Wrba Maximilian F. Reiser Stefan O. Schoenberg | 2007 | European Radiology2007，，7： | 1 |
| 12 | Feasibility of personalized treatment concepts in gastrointestinal malignancies: Sub-group results of prospective clinical phase Ⅱ trial EXACT显示文摘Objective: Advances in high-throughput genomic profiling and the development of new targeted therapies improve patient's survival. In gastrointestinal(GI) malignancies, the concept of personalized medicine(PM) was not investigated so far. The aim of this prospective study was to evaluate the efficacy of a personalized treatment in GI patients who failed standard treatment.Methods: Out of the original prospective clinical phase Ⅱ EXACT trial, 21(38%) GI cancer patients who had no further treatment options were identified. A molecular profile(MP) via a 50 gene next generation sequencing(NGS) panel in combination with immunohistochemistry(IHC) was conducted using real-time biopsy tumor material. Results were discussed by a multidisciplinary team(MDT) to translate the individual MP in an experimental treatment.Results: Of the 55 patients originally included in the EXACT trial, 21(38%) suffered from GI malignancies.The final analysis showed that 15(71%) patients had experienced a longer progression-free survival(PFS) upon experimental targeted treatment(124 d, quartiles 70/193 d), when compared with the PFS achieved by the previous conventional therapy(62 d, quartiles 55/83 d)(P=0.014). Thirteen(62%) patients receiving targeted treatment experienced a disease control according to Response Evaluation Criteria in Solid Tumors(RECIST). Median overall survival(OS) from the start of experimental therapy to time of censoring or death was 193 d(quartiles115/374 d).Conclusions: PM was not investigated in GI malignancies so far in a prospective trial. This study shows that treatment based on real-time molecular tumor profiling led to a superior clinical benefit, and survival as well as response was significantly improved when compared with previous standard medications. | Matthias Unseld Robert Mader Lukas Baumann Clarence Veraar Fritz Wrba Fredrik Waneck Markus Kieler Daniela Bianconi Walter Berger Maria Sibilia Leonhard Miillauer Christoph Zielinski Gerald W. Prager | 2018 | Chinese Journal of Cancer Research2018，30，5： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员